Inhibition of Platelet Absorption

Abstract

A cardiovascular graft is provided with highly reduced thrombogenicity. The cardiovascular graft is an electrospun non-woven mesh produced from supramolecular polymers with large diameter fibers. The cardiovascular graft can be implemented as a vascular graft into the human body to allow vascular bypass/reconstruction, or repeated venous access for dialysis treatment, as well as other disorders of small-diameter blood vessels.

What is claimed is: 
     
         1 . A cardiovascular graft to reduce thrombogenic effects, comprising: a tubular structure with an inner wall made out of a fibrous network of supramolecular compounds having hard-blocks covalently bonded with soft-blocks, wherein the hard-blocks comprise 2-ureido-4[1H]-pyrimidinone (UPy) compounds, wherein the fibrous network is a bioresorbable electrospun non-woven fibrous network with fibers having an average fiber diameter of 1-10 microns, and wherein the tubular structure has an inner diameter between 2-8 mm, and a wall thickness of 200-900 microns. 
     
     
         2 . The cardiovascular graft as set forth in  claim 1 , wherein the inner wall has a thickness of at least 20 micrometers and has pores with an average pore size between 5 and 10 micrometers. 
     
     
         3 . The cardiovascular graft as set forth in  claim 1 , wherein the inner wall has pores with an average pore size between 5 and 8 micrometers and an average porosity ranging from 50 to 80%. 
     
     
         4 . The cardiovascular graft as set forth in  claim 1 , wherein the tubular structure has an inner diameter between 3-6 mm and a wall thickness of 200-800 microns. 
     
     
         5 . The cardiovascular graft as set forth in  claim 1 , wherein the tubular structure has an inner diameter between 4-8 mm and a wall thickness of 300-900 microns. 
     
     
         6 . The cardiovascular graft as set forth in  claim 1 , wherein the tubular structure has an inner diameter of 5 mm or less. 
     
     
         7 . The cardiovascular graft as set forth in  claim 1 , wherein the fibers having an average fiber diameter of 4-8 microns. 
     
     
         8 . The cardiovascular graft as set forth in  claim 1 , wherein the fibers having an average fiber diameter of 4-6 microns. 
     
     
         9 . The cardiovascular graft as set forth in  claim 1 , wherein the soft-blocks comprise a biodegradable polyester, polyurethane, polycarbonate, poly(ortho)ester, polyphosphoester, polyanhydride, polyphosphazene, polyhydroxyalkanoate, polyvinylalcohol, polypropylenefumarate or any combination thereof. 
     
     
         10 . The cardiovascular graft as set forth in  claim 1 , wherein the molecular weight of the soft-block ranges between 500 and 3000 Da. 
     
     
         11 . The cardiovascular graft as set forth in  claim 1 , wherein the hard-blocks further comprise chain extenders at a range of 1 to 5, or even more preferred 1.5 to 3, for the chain extenders over the UPy compounds. 
     
     
         12 . The cardiovascular graft as set forth in  claim 1 , wherein the inner layer of the graft is hydrophobic, with a water contact angle of between 110 and 140 degrees. 
     
     
         13 . The cardiovascular graft as set forth in  claim 1 , wherein the cardiovascular graft is a coronary bypass graft. 
     
     
         14 . The cardiovascular graft as set forth in  claim 1 , wherein the cardiovascular graft is an arteriovenous graft for dialysis access. 
     
     
         15 . The cardiovascular graft as set forth in  claim 1 , wherein the tubular structure has an outer wall reinforced by a braided structure, polymer strands, compounds or a combination thereof to provide resistance to prevent collapse of the cardiovascular graft. 
     
     
         16 . The cardiovascular graft as set forth in  claim 1 , further comprises an α IIb β 3  inhibitor. 
     
     
         17 . A method of implanting the cardiovascular graft as set forth in any one of the  claims 1 - 16 , wherein the implanting of the cardiovascular graft is performed in combination with administering of an α IIb β 3  inhibitor.